Analyses and Correlation of Pathologic and Ocular Cutaneous Changes in Murine Graft versus Host Disease

Use of Post-transplant Cyclophosphamide Treatment to Build a Tolerance Platform to Prevent Liquid and Solid Organ Allograft Rejection

(2021) Casey O. Lightbourn et al.   Frontiers in Immunology

ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease

(2021) Madan Jagasia et al.   JOURNAL OF CLINICAL ONCOLOGY

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

(2020) Madan Jagasia et al.   BLOOD

Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients

(2019) Yu Wang et al.   Journal of Hematology & Oncology

Very Low Numbers of CD4 +  FoxP3 +  Tregs Expanded in Donors via TL1A-Ig and Low-Dose IL-2 Exhibit a Distinct Activation/Functional Profile and Suppress GVHD in a Preclinical Model

(2018) Sabrina Copsel et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets

(2017) Robert Zeiser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel Scoring Criteria for the Evaluation of Ocular Graft-versus-Host Disease in a Preclinical Allogeneic Hematopoietic Stem Cell Transplantation Animal Model

(2016) Victor L. Perez et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Mechanistic approaches for the prevention and treatment of chronic GVHD

(2016) Corey S. Cutler et al.   BLOOD

Incidence and risk factors for ocular GVHD after allogeneic hematopoietic stem cell transplantation

(2015) K-S Na et al.   BONE MARROW TRANSPLANTATION

Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice

(2014) S. Ganguly et al.   BLOOD

Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans

(2014) R. Flynn et al.   BLOOD

Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease

(2014) S. Spoerl et al.   BLOOD

The allure and peril of hematopoietic stem cell transplantation: overcoming immune challenges to improve success

(2013) Robert G. Newman et al.   IMMUNOLOGIC RESEARCH

Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium

(2012) D. A. Jacobsohn et al.   BLOOD

Ocular graft-versus-host disease

(2012) Michelle Hessen et al.   Current Opinion in Allergy and Clinical Immunology

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease

(2011) K. J. Martires et al.   BLOOD

Diagnosis and Treatment of Ocular Chronic Graft-Versus-Host Disease: Report From the German–Austrian–Swiss Consensus Conference on Clinical Practice in Chronic GVHD

(2011) Tina Dietrich-Ntoukas et al.   CORNEA

Limbus Damage in Ocular Graft-versus-Host Disease

(2010) Rebeca Lorenzo Pérez et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Current insights into ocular graft-versus-host disease

(2010) Anjo Riemens et al.   CURRENT OPINION IN OPHTHALMOLOGY

STAT3 Signaling in CD4+ T Cells Is Critical for the Pathogenesis of Chronic Sclerodermatous Graft-Versus-Host Disease in a Murine Model

(2009) V. Radojcic et al.   JOURNAL OF IMMUNOLOGY

Graft-versus-host disease

(2009) James LM Ferrara et al.   LANCET

Ocular Findings after Allogeneic Hematopoietic Stem Cell Transplantation

(2009) Khalid F. Tabbara et al.   OPHTHALMOLOGY